SEARCH

Current Edition

Barron

GSK loses R&D chief Barron to high-powered startup amid investor pressure

Hal Barron, GlaxoSmithKline’s top scientist and architect of the company’s plans to revitalize its drug research, will step down from his role later this year …

Continue Reading →
Adagio

Adagio, after bold promises, says antibody drug won’t work well against omicron

The findings are a huge disappointment for Adagio, which billed ADG20 as a weapon that could neutralize a wide range of variants and help with …

Continue Reading →
AstraZeneca

AstraZeneca wagers $200M on Ionis’ next chance at a rare disease drug

AstraZeneca is betting that Ionis’ second drug for transthyretin amyloidosis, or ATTR, will stand out where its first one couldn’t. Ionis developed Tegsedi for years …

Continue Reading →
GlaxoSmithKline

Pfizer, marking fast research pace, starts key trial of RSV vaccine

A vaccine against RSV has proven elusive despite decades of attempts. Pfizer is moving at a surprisingly quick pace to catch up to rivals led …

Continue Reading →
drugmakers

Pfizer’s fast progress shines spotlight on an emerging vaccine race

Drugmakers have laboured for decades to successfully develop a vaccine to protect infants and older people against infections of a common pathogen called respiratory syncytial …

Continue Reading →
AstraZeneca

AstraZeneca wins first FDA approval for systemic lupus drug in a decade

Benlysta’s approval was itself a landmark, being the first such drug approved in decades. Its use has grown slowly and steadily over time, falling just …

Continue Reading →